Free Trial

Profound Medical (PROF) Competitors

Profound Medical logo
$5.98 -0.11 (-1.72%)
As of 07/3/2025 03:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PROF vs. CBLL, BBNX, AVNS, EMBC, BVS, KIDS, RXST, BFLY, AXGN, and DCTH

Should you be buying Profound Medical stock or one of its competitors? The main competitors of Profound Medical include CeriBell (CBLL), Beta Bionics (BBNX), Avanos Medical (AVNS), Embecta (EMBC), Bioventus (BVS), OrthoPediatrics (KIDS), RxSight (RXST), Butterfly Network (BFLY), AxoGen (AXGN), and Delcath Systems (DCTH). These companies are all part of the "medical equipment" industry.

Profound Medical vs. Its Competitors

Profound Medical (NASDAQ:PROF) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

In the previous week, Profound Medical had 1 more articles in the media than CeriBell. MarketBeat recorded 1 mentions for Profound Medical and 0 mentions for CeriBell. Profound Medical's average media sentiment score of 0.75 beat CeriBell's score of 0.00 indicating that Profound Medical is being referred to more favorably in the media.

Company Overall Sentiment
Profound Medical Positive
CeriBell Neutral

Profound Medical currently has a consensus target price of $11.50, indicating a potential upside of 92.15%. CeriBell has a consensus target price of $32.14, indicating a potential upside of 69.84%. Given Profound Medical's higher possible upside, equities analysts clearly believe Profound Medical is more favorable than CeriBell.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profound Medical
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
CeriBell
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00

CeriBell has a net margin of 0.00% compared to Profound Medical's net margin of -269.35%. CeriBell's return on equity of 0.00% beat Profound Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Profound Medical-269.35% -70.41% -57.22%
CeriBell N/A N/A N/A

Profound Medical has higher earnings, but lower revenue than CeriBell.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profound Medical$10.68M16.84-$27.82M-$1.22-4.91
CeriBell$65.44M10.45-$40.46MN/AN/A

47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 20.1% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Profound Medical and CeriBell tied by winning 6 of the 12 factors compared between the two stocks.

Get Profound Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for PROF and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PROF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PROF vs. The Competition

MetricProfound MedicalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$179.57M$2.43B$5.56B$9.03B
Dividend YieldN/A1.67%5.22%3.99%
P/E Ratio-4.919.3527.6920.25
Price / Sales16.84478.02389.63163.10
Price / CashN/A158.5936.8958.10
Price / Book2.984.588.035.67
Net Income-$27.82M$31.34M$3.18B$249.21M
7 Day Performance-0.25%3.25%2.93%3.28%
1 Month Performance7.45%3.46%1.72%3.95%
1 Year Performance-32.75%0.77%34.39%20.98%

Profound Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PROF
Profound Medical
2.6647 of 5 stars
$5.99
-1.7%
$11.50
+92.1%
-32.8%$179.57M$10.68M-4.91150Negative News
CBLL
CeriBell
1.9061 of 5 stars
$18.73
-0.9%
$32.14
+71.6%
N/A$683.10M$65.44M0.00N/A
BBNX
Beta Bionics
N/A$14.56
-3.4%
$23.44
+61.0%
N/A$653.38M$65.12M0.00294
AVNS
Avanos Medical
N/A$12.25
+0.3%
N/A-36.1%$564.64M$689.20M-1.462,227
EMBC
Embecta
4.147 of 5 stars
$9.69
+0.5%
$19.33
+99.5%
-9.9%$563.39M$1.12B10.772,100
BVS
Bioventus
2.7167 of 5 stars
$6.62
-2.2%
$14.33
+116.5%
+22.5%$543.79M$567.70M-10.851,200Positive News
KIDS
OrthoPediatrics
3.9068 of 5 stars
$21.48
+0.5%
$35.83
+66.8%
-27.1%$519M$204.73M-12.27200
RXST
RxSight
1.7514 of 5 stars
$13.00
+2.6%
$37.90
+191.5%
-76.8%$514.87M$139.93M-19.40220News Coverage
Positive News
BFLY
Butterfly Network
2.4662 of 5 stars
$2.00
+1.8%
$4.00
+100.5%
+102.0%$484.69M$82.06M-6.88460News Coverage
Analyst Forecast
AXGN
AxoGen
2.0301 of 5 stars
$10.85
+3.3%
$22.20
+104.6%
+44.8%$478.21M$187.34M-72.33450Positive News
High Trading Volume
DCTH
Delcath Systems
3.5125 of 5 stars
$13.60
+0.2%
$24.00
+76.5%
+59.9%$472.59M$37.21M-27.2060News Coverage
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:PROF) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners